Vast Therapeutics

Vast Therapeutics is a private, pre-revenue biotech focused on a significant unmet need in chronic respiratory diseases, which affect over 500 million people globally. The company has advanced its lead candidate into Phase 1 clinical trials and has secured non-dilutive grant funding and Orphan Drug Designation, validating its approach. Its pipeline targets specific infections and inflammatory pathways in conditions like cystic fibrosis and bronchiectasis, aiming to improve quality of life and reduce hospitalizations. The company is currently raising capital through a public Reg CF funding round.

Development of novel small molecule therapeutics targeting the cycle of infection and inflammation in chronic lung diseases.

The chronic respiratory disease space is competitive, with several companies developing anti-infectives, anti-inflammatories, and mucolytics for CF and bronchiectasis. Vast must differentiate its mechanism of action. Its focus on specific infection types (e.g., PA, NTM) and orphan status may allow it to carve out a niche against broader-platform competitors.